-
Je něco špatně v tomto záznamu ?
Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study
D. Dudek, A. Dziewierz, P. Widimsky, L. Bolognese, P. Goldstein, C. Hamm, JF. Tanguay, L. LeNarz, DL. Miller, E. Brown, J. Ten Berg, G. Montalescot, . ,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
- MeSH
- elektrokardiografie * MeSH
- infarkt myokardu diagnóza terapie MeSH
- koronární angioplastika metody MeSH
- koronární bypass metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- prasugrel hydrochlorid aplikace a dávkování MeSH
- předoperační péče metody MeSH
- senioři MeSH
- výsledek terapie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
OBJECTIVES: We evaluated impact of timing of coronary artery bypass grafting (CABG) and prasugrel pretreatment in patients with non-ST-segment elevation myocardial infarction undergoing CABG in the ACCOAST study. METHODS: Of 4033 enrolled patients, 314 (7.8%) underwent isolated CABG through 30 days. Primary efficacy end point for this analysis was any cardiovascular death, myocardial infarction, stroke, urgent revascularization, or glycoprotein IIb/IIIa inhibitor bailout through 30 days. RESULTS: More CABG versus percutaneous coronary intervention or medically managed patients were men, diabetic, or had peripheral arterial disease. Per randomization, 157 of 314 patients received a 30-mg prasugrel loading dose before CABG, and 157 of 314 received placebo. Patients were stratified by tertile of time from randomization to CABG: <2.98 days (n = 104), ≥2.98 and <6.95 days (n = 106), and ≥6.95 days (n = 104). Primary end point occurred in 12.5%, 4.7%, and 4.8%, respectively (<2.98 days vs other tertiles, hazard ratio [HR] = 2.80; P = .011). Similarly, the rate of all TIMI major bleeding was highest in the lowest tertile (26.0% vs 10.4% and 4.8%; P < .001), but no difference in all-cause death was observed through 30 days (3.9% vs 1.9% and 1.9%; P = .30). Time from randomization to CABG (HR = 0.84 for each day delay), left main disease (HR = 1.76), region of enrollment (Non-Eastern Europe vs Eastern Europe; HR = 3.83), but not prasugrel pretreatment and baseline troponin ≥3× upper limit of normal, were independent predictors of combined 30-day end point of all-cause death/myocardial infarction/stroke/TIMI major bleeding. CONCLUSIONS: In ACCOAST, early (<2.98 days) surgical revascularization carried increased risk of bleeding and ischemic complications without affecting all-cause mortality through 30 days. Baseline troponin and prasugrel pretreatment did not impact ischemic clinical outcomes.
Cardiovascular and Neurological Department Azienda Ospedaliera Arezzo Italy
Department of Cardiology St Antonius Hospital Nieuwegein Netherlands
Department of Interventional Cardiology Jagiellonian University Medical College Krakow Poland
Eli Lilly and Company Lilly Corporate Center Indianapolis IN USA
Kerckhoff Heart and Thorax Center Bad Nauheim Germany
Montreal Heart Institute Université de Montréal Montreal Quebec Canada
SAMU and Emergency Department Lille University Hospital Lille France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16009913
- 003
- CZ-PrNML
- 005
- 20160411130052.0
- 007
- ta
- 008
- 160408s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ahj.2015.07.017 $2 doi
- 024 7_
- $a 10.1016/j.ahj.2015.07.017 $2 doi
- 035 __
- $a (PubMed)26542513
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Dudek, Dariusz $u Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland. Electronic address: mcdudek@cyfronet.pl.
- 245 10
- $a Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study / $c D. Dudek, A. Dziewierz, P. Widimsky, L. Bolognese, P. Goldstein, C. Hamm, JF. Tanguay, L. LeNarz, DL. Miller, E. Brown, J. Ten Berg, G. Montalescot, . ,
- 520 9_
- $a OBJECTIVES: We evaluated impact of timing of coronary artery bypass grafting (CABG) and prasugrel pretreatment in patients with non-ST-segment elevation myocardial infarction undergoing CABG in the ACCOAST study. METHODS: Of 4033 enrolled patients, 314 (7.8%) underwent isolated CABG through 30 days. Primary efficacy end point for this analysis was any cardiovascular death, myocardial infarction, stroke, urgent revascularization, or glycoprotein IIb/IIIa inhibitor bailout through 30 days. RESULTS: More CABG versus percutaneous coronary intervention or medically managed patients were men, diabetic, or had peripheral arterial disease. Per randomization, 157 of 314 patients received a 30-mg prasugrel loading dose before CABG, and 157 of 314 received placebo. Patients were stratified by tertile of time from randomization to CABG: <2.98 days (n = 104), ≥2.98 and <6.95 days (n = 106), and ≥6.95 days (n = 104). Primary end point occurred in 12.5%, 4.7%, and 4.8%, respectively (<2.98 days vs other tertiles, hazard ratio [HR] = 2.80; P = .011). Similarly, the rate of all TIMI major bleeding was highest in the lowest tertile (26.0% vs 10.4% and 4.8%; P < .001), but no difference in all-cause death was observed through 30 days (3.9% vs 1.9% and 1.9%; P = .30). Time from randomization to CABG (HR = 0.84 for each day delay), left main disease (HR = 1.76), region of enrollment (Non-Eastern Europe vs Eastern Europe; HR = 3.83), but not prasugrel pretreatment and baseline troponin ≥3× upper limit of normal, were independent predictors of combined 30-day end point of all-cause death/myocardial infarction/stroke/TIMI major bleeding. CONCLUSIONS: In ACCOAST, early (<2.98 days) surgical revascularization carried increased risk of bleeding and ischemic complications without affecting all-cause mortality through 30 days. Baseline troponin and prasugrel pretreatment did not impact ischemic clinical outcomes.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a koronární bypass $x metody $7 D001026
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 12
- $a elektrokardiografie $7 D004562
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a infarkt myokardu $x diagnóza $x terapie $7 D009203
- 650 _2
- $a koronární angioplastika $x metody $7 D062645
- 650 _2
- $a prasugrel hydrochlorid $x aplikace a dávkování $7 D000068799
- 650 _2
- $a předoperační péče $x metody $7 D011300
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dziewierz, Artur $u Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland.
- 700 1_
- $a Widimsky, Petr $u Third Medical Faculty of Charles University and University Hospital Royal Vineyards, Prague, Czech Republic.
- 700 1_
- $a Bolognese, Leonardo $u Cardiovascular and Neurological Department, Azienda Ospedaliera, Arezzo, Italy.
- 700 1_
- $a Goldstein, Patrick $u SAMU and Emergency Department, Lille University Hospital, Lille, France.
- 700 1_
- $a Hamm, Christian $u Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.
- 700 1_
- $a Tanguay, Jean-Francois $u Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
- 700 1_
- $a LeNarz, LeRoy $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
- 700 1_
- $a Miller, Debra L $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
- 700 1_
- $a Brown, Eileen $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
- 700 1_
- $a Ten Berg, Jurrien $u Department of Cardiology, St. Antonius Hospital, Nieuwegein, Netherlands.
- 700 1_
- $a Montalescot, Gilles $u ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtriėre (AP-HP), Université Paris 6, Paris, France.
- 700 1_
- $a ,
- 773 0_
- $w MED00000228 $t American heart journal $x 1097-6744 $g Roč. 170, č. 5 (2015), s. 1025-1032.e2
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26542513 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160411130134 $b ABA008
- 999 __
- $a ok $b bmc $g 1113342 $s 934281
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 170 $c 5 $d 1025-1032.e2 $e 20150726 $i 1097-6744 $m The American heart journal $n Am Heart J $x MED00000228
- LZP __
- $a Pubmed-20160408
